Literature DB >> 28081607

Structure-Activity Relationships of Spectinamide Antituberculosis Agents: A Dissection of Ribosomal Inhibition and Native Efflux Avoidance Contributions.

Jiuyu Liu1, David F Bruhn1, Robin B Lee1, Zhong Zheng1, Tanja Janusic2, Dimitri Scherbakov2, Michael S Scherman3, Helena I Boshoff4, Sourav Das1, Samanthi L Waidyarachchi1, Tiffany A Brewer1,5, Begoña Gracia6, Lei Yang1, John Bollinger1, Gregory T Robertson3, Bernd Meibohm5, Anne J Lenaerts3, Jose Ainsa6, Erik C Böttger2, Richard E Lee1.   

Abstract

Spectinamides are a novel class of antitubercular agents with the potential to treat drug-resistant tuberculosis infections. Their antitubercular activity is derived from both ribosomal affinity and their ability to overcome intrinsic efflux mediated by the Mycobacterium tuberculosis Rv1258c efflux pump. This study explores the structure-activity relationships through analysis of 50 targeted spectinamides. Compounds are evaluated for ribosomal translational inhibition, MIC activity in Rv1258c efflux pump deficient and wild type tuberculosis strains, and efficacy in an acute model of tuberculosis infection. The results of this study show a narrow structure-activity relationship, consistent with a tight ribosome-binding pocket and strict structural requirements to overcome native efflux. Rationalization of ribosomal inhibition data using molecular dynamics simulations showed stable complex formation for halogenated spectinamides consistent with the long post antibiotic effects observed. The lead spectinamides identified in this study demonstrated potent MIC activity against MDR and XDR tuberculosis and had desirable antitubercular class specific features including low protein binding, low microsomal metabolism, no cytotoxicity, and significant reductions in bacterial burdens in the lungs of mice infected with M. tuberculosis. The structure-activity relationships detailed here emphasize the need to examine efflux-mediated resistance in the design of antituberculosis drugs and demonstrate that it is possible to overcome intrinsic efflux with synthetic modification. The ability to understand the structure requirements for this class has produced a variety of new substituted spectinamides, which may provide useful alternative candidates and promote the further development of this class.

Entities:  

Keywords:  antituberculosis; efficacy; efflux pump; spectinamide; spectinomycin; structure−activity relationship

Mesh:

Substances:

Year:  2016        PMID: 28081607      PMCID: PMC5493200          DOI: 10.1021/acsinfecdis.6b00158

Source DB:  PubMed          Journal:  ACS Infect Dis        ISSN: 2373-8227            Impact factor:   5.084


  26 in total

1.  Development and testing of a general amber force field.

Authors:  Junmei Wang; Romain M Wolf; James W Caldwell; Peter A Kollman; David A Case
Journal:  J Comput Chem       Date:  2004-07-15       Impact factor: 3.376

2.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.

Authors:  Richard A Friesner; Jay L Banks; Robert B Murphy; Thomas A Halgren; Jasna J Klicic; Daniel T Mainz; Matthew P Repasky; Eric H Knoll; Mee Shelley; Jason K Perry; David E Shaw; Perry Francis; Peter S Shenkin
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

3.  Efflux pumps of Mycobacterium tuberculosis play a significant role in antituberculosis activity of potential drug candidates.

Authors:  Meenakshi Balganesh; Neela Dinesh; Sreevalli Sharma; Sanjana Kuruppath; Anju V Nair; Umender Sharma
Journal:  Antimicrob Agents Chemother       Date:  2012-02-06       Impact factor: 5.191

4.  Aminomethyl spectinomycins as therapeutics for drug-resistant respiratory tract and sexually transmitted bacterial infections.

Authors:  David F Bruhn; Samanthi L Waidyarachchi; Dora B Madhura; Dimitri Shcherbakov; Zhong Zheng; Jiuyu Liu; Yasser M Abdelrahman; Aman P Singh; Stefan Duscha; Chetan Rathi; Robin B Lee; Robert J Belland; Bernd Meibohm; Jason W Rosch; Erik C Böttger; Richard E Lee
Journal:  Sci Transl Med       Date:  2015-05-20       Impact factor: 17.956

5.  The tolerance of high dose intravenous spectinomycin therapy in man.

Authors:  E Novak; C A Schlagel; L A LeZotte; R T Pfeifer
Journal:  J Clin Pharmacol       Date:  1974 Aug-Sep       Impact factor: 3.126

6.  Synthesis and in vitro antibacterial properties of alkylspectinomycin analogs.

Authors:  D R White; C J Maring; G A Cain
Journal:  J Antibiot (Tokyo)       Date:  1983-03       Impact factor: 2.649

Review 7.  Advances in Drug Discovery and Development for Pediatric Tuberculosis.

Authors:  Daniel Hoagland; Ying Zhao; Richard E Lee
Journal:  Mini Rev Med Chem       Date:  2016       Impact factor: 3.862

8.  A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents.

Authors:  Julian G Hurdle; Robin B Lee; Nageshwar R Budha; Elizabeth I Carson; Jianjun Qi; Michael S Scherman; Sang Hyun Cho; Michael R McNeil; Anne J Lenaerts; Scott G Franzblau; Bernd Meibohm; Richard E Lee
Journal:  J Antimicrob Chemother       Date:  2008-08-07       Impact factor: 5.790

9.  Spectinomycin chemistry. III.9-EPI-4(R)-dihydrospectinomycin and 9-epi-spectinomycin.

Authors:  L Foley; J T Lin; M Weigele
Journal:  J Antibiot (Tokyo)       Date:  1978-10       Impact factor: 2.649

10.  Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux.

Authors:  Richard E Lee; Julian G Hurdle; Jiuyu Liu; David F Bruhn; Tanja Matt; Michael S Scherman; Bernd Meibohm; Erik C Böttger; Anne J Lenaerts; Pavan K Vaddady; Zhong Zheng; Jianjun Qi; Rashid Akbergenov; Sourav Das; Dora B Madhura; Chetan Rathi; Ashit Trivedi; Cristina Villellas; Robin B Lee; Samanthi L Waidyarachchi; Dianqing Sun; Michael R McNeil; Jose A Ainsa; Helena I Boshoff; Mercedes Gonzalez-Juarrero
Journal:  Nat Med       Date:  2014-01-26       Impact factor: 53.440

View more
  15 in total

1.  Development and Characterization of a Dry Powder Formulation for Anti-Tuberculosis Drug Spectinamide 1599.

Authors:  Ian E Stewart; Pradeep B Lukka; Jiuyu Liu; Bernd Meibohm; Mercedes Gonzalez-Juarrero; Miriam S Braunstein; Richard E Lee; Anthony J Hickey
Journal:  Pharm Res       Date:  2019-07-18       Impact factor: 4.200

2.  Comparative pharmacokinetics of spectinamide 1599 after subcutaneous and intrapulmonary aerosol administration in mice.

Authors:  Chetan Rathi; Pradeep B Lukka; Santosh Wagh; Richard E Lee; Anne J Lenaerts; Miriam Braunstein; Anthony Hickey; Mercedes Gonzalez-Juarrero; Bernd Meibohm
Journal:  Tuberculosis (Edinb)       Date:  2018-12-31       Impact factor: 3.131

Review 3.  Drug-resistance in Mycobacterium tuberculosis: where we stand.

Authors:  Amanda Mabhula; Vinayak Singh
Journal:  Medchemcomm       Date:  2019-06-11       Impact factor: 3.597

Review 4.  Molecule Property Analyses of Active Compounds for Mycobacterium tuberculosis.

Authors:  Vadim Makarov; Elena Salina; Robert C Reynolds; Phyo Phyo Kyaw Zin; Sean Ekins
Journal:  J Med Chem       Date:  2020-04-20       Impact factor: 7.446

5.  Development of BODIPY FL Thalidomide As a High-Affinity Fluorescent Probe for Cereblon in a Time-Resolved Fluorescence Resonance Energy Transfer Assay.

Authors:  Wenwei Lin; Yongtao Li; Jaeki Min; Jiuyu Liu; Lei Yang; Richard E Lee; Taosheng Chen
Journal:  Bioconjug Chem       Date:  2020-10-18       Impact factor: 4.774

6.  Efficacy of Aminomethyl Spectinomycins against Complex Upper Respiratory Tract Bacterial Infections.

Authors:  Amy Iverson; Christopher J Meyer; Peter Vogel; Samanthi Waidyarachchi; Nisha Das; David F Bruhn; Aaron Poole; Michelle M Butler; Terry L Bowlin; Richard E Lee; Jason W Rosch
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

7.  Model-Based Exposure-Response Assessment for Spectinamide 1810 in a Mouse Model of Tuberculosis.

Authors:  Santosh Wagh; Chetan Rathi; Pradeep B Lukka; Keyur Parmar; Zaid Temrikar; Jiuyu Liu; Michael S Scherman; Richard E Lee; Gregory T Robertson; Anne J Lenaerts; Bernd Meibohm
Journal:  Antimicrob Agents Chemother       Date:  2021-08-23       Impact factor: 5.191

Review 8.  The present state of the tuberculosis drug development pipeline.

Authors:  M Daben J Libardo; Helena Im Boshoff; Clifton E Barry
Journal:  Curr Opin Pharmacol       Date:  2018-08-23       Impact factor: 5.547

9.  Sugar-Pirating as an Enabling Platform for the Synthesis of 4,6-Dideoxyhexoses.

Authors:  Yinan Zhang; Jianjun Zhang; Larissa V Ponomareva; Zheng Cui; Steven G Van Lanen; Jon S Thorson
Journal:  J Am Chem Soc       Date:  2020-05-07       Impact factor: 15.419

10.  Synthesis, antibacterial action, and ribosome inhibition of deoxyspectinomycins.

Authors:  Suresh Dharuman; Laura A Wilt; Jiuyu Liu; Stephanie M Reeve; Carl W Thompson; John M Elmore; Dimitri Shcherbakov; Robin B Lee; Erik C Böttger; Richard E Lee
Journal:  J Antibiot (Tokyo)       Date:  2021-01-27       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.